[go: up one dir, main page]

AU1868195A - Cell signaling inhibitors - Google Patents

Cell signaling inhibitors

Info

Publication number
AU1868195A
AU1868195A AU18681/95A AU1868195A AU1868195A AU 1868195 A AU1868195 A AU 1868195A AU 18681/95 A AU18681/95 A AU 18681/95A AU 1868195 A AU1868195 A AU 1868195A AU 1868195 A AU1868195 A AU 1868195A
Authority
AU
Australia
Prior art keywords
cell signaling
signaling inhibitors
inhibitors
cell
signaling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18681/95A
Inventor
J. Peter Klein
Anil Kumar
Alistair J Leigh
Glenn C Rice
Gail E Underiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of AU1868195A publication Critical patent/AU1868195A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU18681/95A 1994-01-28 1995-01-27 Cell signaling inhibitors Abandoned AU1868195A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18849194A 1994-01-28 1994-01-28
US188491 1994-01-28
PCT/US1995/001037 WO1995020589A1 (en) 1994-01-28 1995-01-27 Cell signaling inhibitors

Publications (1)

Publication Number Publication Date
AU1868195A true AU1868195A (en) 1995-08-15

Family

ID=22693376

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18681/95A Abandoned AU1868195A (en) 1994-01-28 1995-01-27 Cell signaling inhibitors

Country Status (2)

Country Link
AU (1) AU1868195A (en)
WO (1) WO1995020589A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
EP0814809B1 (en) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
ES2254163T3 (en) * 1999-04-09 2006-06-16 Cell Therapeutics, Inc. THERAPEUTIC COMPOUNDS TO INHIBIT THE SIGNALING OF INTERLEUCINE-12 AND METHODS FOR THE USE OF THE SAME.
US6586429B2 (en) 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
AU2003243285A1 (en) 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
WO2005077950A2 (en) 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EA200800564A1 (en) 2005-08-10 2008-08-29 Смитклайн Бичам Корпорейшн DERIVATIVES OF XANTHINE AS SELECTIVE AGONISTS NM74A
CA3075880A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
CA3105099A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
EP3937940A4 (en) 2019-03-15 2022-12-21 Forma Therapeutics, Inc. INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3258491A (en) * 1966-06-28 Oxidation op olefins to ketones
ES416696A1 (en) * 1972-07-12 1976-02-16 Albert Ag Chem Werke Procedure for the preparation of oxoalcohylxantinas. (Machine-translation by Google Translate, not legally binding)
DE2330742C2 (en) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1- (Oxoalkyl) -3-methyl-7-alkylxanthines, process for their preparation and pharmaceuticals containing them
US4203927A (en) * 1978-04-11 1980-05-20 Phillips Petroleum Company Olefin oxidation process
JPS5653680A (en) * 1979-10-05 1981-05-13 Hamari Yakuhin Kogyo Kk Preparation of 1-(5'-oxohexyl)-theobromine
JPS5668681A (en) * 1979-11-10 1981-06-09 Nissei Kagaku Kogyosho:Kk Preparation of xanthine derivative
JPS58150594A (en) * 1982-03-03 1983-09-07 Daito Koeki Kk Preparation of xanthine derivative

Also Published As

Publication number Publication date
WO1995020589A1 (en) 1995-08-03

Similar Documents

Publication Publication Date Title
PL324491A1 (en) Cell adhesion inhibitors
AU3832895A (en) Thrombin inhibitors
AU4269896A (en) Fibronectin adhesion inhibitors
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU1817095A (en) Block copolymers
IL125126A0 (en) Electroconversion cell
PL321759A1 (en) Novel thrombosin inhibitors
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
AU6138594A (en) Electrochemical fulleren system
PL331803A1 (en) Bidonoric metaloprotease inhibitors
AU1868195A (en) Cell signaling inhibitors
AU1614595A (en) Battery
AU692123B2 (en) 5alpha-reductase inhibitors
AU6090594A (en) Angiotensin ii inhibitors
AU2832399A (en) B cell inhibitors
GB9425701D0 (en) Enzyme inhibitors
AU6702894A (en) Ring-substituted cell signaling inhibitors
HU9503783D0 (en) Squvalen syntetase inhibitors
AU693274B2 (en) Air-droppable buoy
AU1013997A (en) Amylase inhibitors
AU3923395A (en) Order-picking cell
AU2402995A (en) Storage system
AU6049796A (en) Lysyloxidase inhibitors
AU3929195A (en) Storage system
AU2812195A (en) Inhibitor